Abstract:Herb-drug interactions may potentially affect drug efficacy and/or the likelihood of adverse drug reactions. Radix Astragali (RA) extract formulation is usually prescribed for long-term use for patients with immunodeficiency, diabetes, nephropathy or cardiovascular diseases. Its use in combination with P-glycoprotein (P-gp) substrates is possible in clinical practice. Currently there is little knowledge about whether concomitant use of RA extract has an influence on disposition of P-gp substrate.This study was to investigate whether continuous and multiple doses of RA extract granules had modulatory effects on human P-gp.A randomised, placebo-controlled, two-period crossover pharmacokinetic drug interaction study was conducted in healthy Chinese volunteers. Fexofenadine was used as a P-gp phenotyping probe. Fourteen volunteers received RA extract granules or placebo (4g bid) for 7 days and then received a single oral dose of 120mg fexofenadine. Fexofenadine plasma concentrations were determined by HPLC. Pharmacokinetic parameters were calculated by non-compartmental method and bioequivalence evaluation was performed.Pharamcokinetic parameters in the placebo phase were as follows: T1/2 (3.75±1.47h), Cmax (745.11±137.41μg/L), Tmax (2.25±0.47h), AUC(0-t) (3894.27±923.45μgh/L), AUC(0-∞) (3993.84±912.97μgh/L). Pharamcokinetic parameters in the RA extract phase were as follows: T1/2 (4.00±1.24h), Cmax (709.44±170.03μg/L), Tmax (2.21±0.51h), AUC(0-t) (3832.72±1077.60μgh/L), AUC(0-∞) (3983.53±1019.83μgh/L). The influence of RA extract on fexofenadine Cmax and AUC lacks statistical significance. Fexofenadine in the two phases were bioequivalent. In the placebo phase, T1/2 of fexofenadine in ABCB1 3435T mutation allele carriers was longer compared to ABCB1 3435CC carriers (4.43±1.44h vs. 2.54±0.21h, p<0.05). However, RA extract pretreatment abolished such genotype-related difference due to the lengthened T1/2 in ABCB1 3435CC carriers. There was no association of the C3435T polymorphism with Cmax and AUC(0-t) in subjects with two pretreatments.One-week administration of RA extract granules did not have a statistically significant impact on systematic exposure to fexofenadine, suggesting that RA extract is not a potent modulator of P-gp in vivo. RA extract appears to have ABCB1 C3435T genotype-dependent inhibitory effect on elimination rather than absorption of a P-gp substrate. Further investigations are necessary in patients who receive long-term use of RA extract formulation and combined P-gp substrates, especially in those ABCB1 3435CC carriers.

In Vitro and in Vivo Evaluation of the Effects of Duloxetine on P-gp Function.

[Interaction Between (E)-2-(4-(diethylamino Methyl) Benzylidene)-5,6-dimethoxy-2,3-dihydroinden-one and P-glycoprotein].

Effects of P-Glycoprotein on the Transport of DL0410, a Potential Multifunctional Anti-Alzheimer Agent.

Study on the Rat Intestinal Absorption Kinetics of Duloxetine Hydrochloride in Vitro

Construction and Application of Double-Transfected Cells Expressing the Human Transporter P-glycoprotein and Cytochrome P450 3A4.

Effect of D, L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol and tetrandrine on the reversion of multidrug resistance in K562/A02 cells.

Effect of Schisandra Chinensis Extract and Ginkgo Biloba Extract on the Pharmacokinetics of Talinolol in Healthy Volunteers.

In Vitro Study of the Effect of Cyclosporine A, Tetrandrine and Their Combination on the Reversion of Multidrug Resistance in Leukemia Cell Line.

Inhibitory Effects of Benzaldehyde, Vanillin, Muscone and Borneol on P-Glycoprotein in Caco-2 Cells and Everted Gut Sac

Effect of genistein on the activities of cytochrome P450 3A and P-glycoprotein in Chinese healthy participants

Reversal Effect of Oxypeucedanin on P-glycoprotein-mediated Drug Transport

Reversal of P-gp Mediated Multidrug Resistance In-Vitro and In-Vivo by FG020318

Investigation on modulation of human P-gp by multiple doses of Radix Astragali extract granules using fexofenadine as a phenotyping probe.

Permeation of Astilbin and Taxifolin in Caco-2 Cell and Their Effects on the P-gp.

Effect of p38 MAPK on the Expression of P-glycoprotein in Multidrug Resistant K562

High-content imaging of human hepatic spheroids for researching the mechanism of duloxetine-induced hepatotoxicity

Role Of P-Glycoprotein In The Intestinal Absorption Of Glabridin, An Active Flavonoid From The Root Of Glycyrrhiza Glabra

In Vitro Investigations into the Potential Drug Interactions of Pseudoginsenoside DQ Mediated by Cytochrome P450 and Human Drug Transporters

Synthesis and biological evaluation of thiophenylbenzofuran derivatives as potential P-glycoprotein inhibitors

Hz08 Reverse P-Glycoprotein Mediated Multidrug Resistance In Vitro And In Vivo

Dose-Dependent Targeted Suppression of P-glycoprotein Expression and Function in Caco-2 Cells